Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

por Axelsen, Lene Nygaard, Poggesi, Italo, Rasschaert, Freya, Perez Ruixo, Juan Jose, Bruderer, Shirin
Publicado 2020

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

por Kaufmann, Priska, Okubo, Kaori, Bruderer, Shirin, Mant, Tim, Yamada, Tetsuhiro, Dingemanse, Jasper, Mukai, Hideya
Publicado 2015

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist

por Hoch, Matthias, Darpo, Borje, Remenova, Tatiana, Stoltz, Randall, Zhou, Meijian, Kaufmann, Priska, Bruderer, Shirin, Dingemanse, Jasper
Publicado 2014

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

por Csonka, Dénes, Bruderer, Shirin, Schultz, Armin, Soergel, Marianne, Stepanova, Radka, Sabattini, Giancarlo, Perez-Ruixo, Juan Jose
Publicado 2019

Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects

por Grill, Simon, Bruderer, Shirin, Sidharta, Patricia N., Antonova, Mariya, Globig, Susanne, Carlson, James, Schultz, Armin, Csonka, Dénes
Publicado 2020

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

por Bruderer, Shirin, Äänismaa, Päivi, Homery, Marie-Claude, Häusler, Stephanie, Landskroner, Kyle, Sidharta, Patricia N., Treiber, Alexander, Dingemanse, Jasper
Publicado 2011